UroGen Pharma Ltd.
General ticker "URGN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $611.1M (TTM average)
UroGen Pharma Ltd. follows the US Stock Market performance with the rate: 49.2%.
Estimated limits based on current volatility of 6.3%: low 24.22$, high 27.20$
Factors to consider:
- Total employees count: 235 as of 2024
- Top business risk factors: Regulatory and compliance, Product liability, Manufacturing and commercialization risks, Cybersecurity threats, Operational and conduct risks
- Current price 68.2% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [5.75$, 14.43$]
- 2025-12-31 to 2026-12-31 estimated range: [4.91$, 12.46$]
Financial Metrics affecting the URGN estimates:
- Negative: with PPE of -3.3 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -21.02 <= 0.33
- Positive: Interest expense per share per price, % of 2.72 <= 3.41
- Negative: Shareholder equity ratio, % of 0.04 <= 18.93
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term URGN quotes
Long-term URGN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 |
|---|---|---|
| Operating Revenue | $82.71MM | $90.40MM |
| Operating Expenses | $148.25MM | $187.18MM |
| Operating Income | $-65.54MM | $-96.78MM |
| Non-Operating Income | $-32.79MM | $-27.26MM |
| Interest Expense | $14.71MM | $12.52MM |
| R&D Expense | $45.61MM | $57.15MM |
| Income(Loss) | $-98.32MM | $-124.04MM |
| Taxes | $3.92MM | $2.83MM |
| Profit(Loss)* | $-102.24MM | $-126.87MM |
| Stockholders Equity | $-65.21MM | $0.12MM |
| Inventory | $5.67MM | $9.23MM |
| Assets | $178.31MM | $285.71MM |
| Operating Cash Flow | $-76.38MM | $-96.77MM |
| Capital expenditure | $0.19MM | $0.29MM |
| Investing Cash Flow | $-0.95MM | $-20.61MM |
| Financing Cash Flow | $116.93MM | $194.62MM |
| Earnings Per Share** | $-3.55 | $-2.96 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.